Latest Biogen News & Updates

See the latest news and media coverage for Biogen. We track all announcements, press releases, and industry mentions in real time, all in one place.

Biogen

Biotechnology company for neurological, immune, and rare diseases

biogen.com

Headquarters: Cambridge, United States
Company type: Public company
Number of employees: 7,500–10,000
Industry: Pharmaceuticals

Last updated Today

Latest news about Biogen

In short: Biogen achieved strong Q2 revenue growth, secured key global approvals for its Alzheimer’s portfolio, and completed the RayThera acquisition.

Company announcements

Today Biogen

Biogen announces LEQEMBI Pen approval in Japan

The subcutaneous formulation for early Alzheimer's disease enables weekly at-home administration by patients or care partners.

August 24 Biogen

Biogen launches LEQEMBI IQLIK autoinjector for early Alzheimer's treatment

This subcutaneous injection offers home dosing convenience and flexibility, expanding treatment access for patients with mild cognitive impairment or mild dementia.

August 6 Biogen

Biogen completes acquisition of RayThera Inc

The deal adds multiple potential assets for immune-mediated diseases, including a lead program in Phase 1 development, growing Biogen's immunology portfolio.

August 3 Biogen

Biogen welcomes Michael Parini as Chief Legal Officer

He brings over 20 years of legal and strategic leadership in healthcare. He will help execute Biogen's strategy and build its future.

Media coverage

Today Yahoo Finance

LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Approved in Japan for the Treatment of Early Alzheimer's Disease

The First and Only Anti-Amyloid Treatment in Japan that Enable At-Home Administration for Alzheimer's Disease, a Progressive DiseaseTOKYO and CAMBRIDGE, Mass., Sept. 16, 2026 (GLOBE...

Yesterday Independent Journal Review

Biogen Wins China Approval for At-Home Alzheimer's Treatment

Biogen won China NMPA approval for a self-administered, weekly at-home LEQEMBI dose for early Alzheimer's, expanding access and reinforcing its strategy to simplify treatment in...

September 9 CNBC

Watch CNBC's full interview with Biogen CEO Christopher Viehbacher

Biogen CEO Christopher Viehbacher joins 'Squawk on the Street' to discuss their upcoming product pipeline, developments in Alzheimer treatment and medication and more.

September 8 Law360

Biogen Must Face Pharmacies' MS Drug Monopoly Suit - Law360

An Illinois federal judge on Tuesday refused to dismiss Walgreens and Kroger's lawsuit accusing Biogen Inc. of illegally stifling competition for its multiple sclerosis drug...

Never miss news about Biogen

Track Biogen and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Biogen competitors & trending companies

Browse news for competitors to Biogen and other trending companies.